☆ 4.8 Review

Novel strategies to prevent and overcome relapse after allogeneic hematopoietic cell transplantation in acute lymphoblastic leukemia

FRONTIERS IN IMMUNOLOGY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Biophysics

Combining blinatumomab and donor lymphocyte infusion in B-ALL patients relapsing after allogeneic hematopoietic cell transplantation: a study of the SFGM-TC

Paul Chauvet et al.

Summary: This study compared the efficacy and safety of blinatumomab with donor lymphocyte infusion (DLI) versus blinatumomab alone in relapsed B-cell acute lymphoblastic leukemia (B-ALL) after allogeneic stem cell transplantation (allo-HCT). The results showed that adding DLI to blinatumomab treatment did not improve outcomes in B-ALL patients who relapsed after allo-HCT.

BONE MARROW TRANSPLANTATION (2023)

添加到收藏夹

Review Hematology

Switching from salvage chemotherapy to immunotherapy in adult B-cell acute lymphoblastic leukemia

David Kegyes et al.

Summary: About half of adults with acute B-cell lymphoblastic leukemia (B-ALL) who do not achieve complete remission or relapse are not cured by current therapies. Immune therapies, including monoclonal antibodies, BiTEs, ADCs, and CARs, have shown effectiveness in this setting. This manuscript summarizes FDA-approved immune therapies for advanced adult B-ALL, their efficacy, safety, QoL, and future directions.

BLOOD REVIEWS (2023)

添加到收藏夹

Article Hematology

Donor-derived multiple leukemia antigen-specific T-cell therapy to prevent relapse after transplant in patients with ALL

Swati Naik et al.

Summary: Infusion of donor-derived multiple leukemia antigen-specific T cells may prevent disease relapse in patients with acute lymphoblastic leukemia (ALL) by targeting leukemia cells and minimizing the risk of graft-versus-host disease.

BLOOD (2022)

添加到收藏夹

Letter Hematology

Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study

Marco Cerrano et al.

HAEMATOLOGICA (2022)

添加到收藏夹

Article Hematology

Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia

Mahmoud R. Gaballa et al.

Summary: This study examined the feasibility and efficacy of blinatumomab in high-risk acute lymphoblastic leukemia patients after allogeneic hematopoietic cell transplantation. The results showed that blinatumomab treatment was feasible and effective in reducing the risk of relapse, with specific T-cell profiles associated with treatment response.

BLOOD (2022)

添加到收藏夹

Article Oncology

Pharmacologic Strategies for Post-Transplant Maintenance in Acute Myeloid Leukemia: It Is Time to Consider!

Iman Abou Dalle et al.

Summary: Allogeneic hematopoietic cell transplantation (allo-HCT) is an important therapeutic procedure for high risk acute myeloid leukemia, but relapse remains a challenge. Strategies such as close monitoring, reducing immunosuppression, and pharmacologic interventions can help control leukemia clones and reduce the risk of relapse.

CANCERS (2022)

添加到收藏夹

Article Hematology

Relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia: an overview of prevention and treatment

Firas Kreidieh et al.

Summary: This article provides an overview of prevention and treatment of relapse in patients with acute myeloid leukemia (AML) post-allogeneic hematopoietic stem cell transplantation (allo-HSCT), including cell-based and pharmacologic options. The effectiveness of post-transplant maintenance therapy, pre-emptive treatment, and prophylactic donor lymphocyte infusion (DLI) in preventing relapse is discussed. Targeted post-transplant pharmacological interventions and the potential role of CAR-T cells in AML are also mentioned.

INTERNATIONAL JOURNAL OF HEMATOLOGY (2022)

添加到收藏夹

Article Oncology

Safety and outcomes of maintenance therapy with third-generation tyrosine kinase inhibitor after allogeneic hematopoietic cell transplantation in Philadelphia chromosome positive acute lymphoblastic leukemia patients with T315I mutation

Huan Chen et al.

Summary: This study evaluated the safety and outcomes of ponatinib maintenance therapy after hematopoietic cell transplantation (HCT) in patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) who harbor the T315I mutation. The results showed that maintenance therapy with ponatinib is safe after HCT, and patients with T315I mutation who received prophylactic regimen showed promising results with an acceptable relapse rate and encouraging survival.

LEUKEMIA RESEARCH (2022)

添加到收藏夹

Review Oncology

Changing Landscape in the Treatment of Adult Acute Lymphoblastic Leukemia (ALL)

Tina Kuenz et al.

Summary: Improved understanding of acute lymphoblastic leukemia has led to new treatment strategies, including measurable residual disease assessment and allogeneic stem cell transplantation. Novel therapeutic opportunities, such as tyrosine-kinase inhibitors and CAR-T cells, aim to improve clinical outcomes. Despite advancements, acute lymphoblastic leukemia remains a challenging and life-threatening disease.

CANCERS (2022)

添加到收藏夹

Article Hematology

The role of ponatinib in adult BCR-ABL1 positive acute lymphoblastic leukemia after allogeneic transplantation: a real-life retrospective multicenter study

Salvatore Leotta et al.

Summary: This retrospective study collected data on 25 Ph'+ ALL patients who received ponatinib treatment post-allogeneic transplantation. Among the patients who received ponatinib as pre-emptive or salvage treatment, 75% achieved complete molecular response. The estimated 2-year overall survival rate was 65%, with a lower rate of 40% for patients with T315I-positive mutational status. However, 56% of patients experienced treatment-related toxicity.

ANNALS OF HEMATOLOGY (2021)

添加到收藏夹

Article Oncology

Efficacy and Safety of Chimeric Antigen Receptor T Cells in Acute Lymphoblastic Leukemia With Post-Transplant Relapse

Lijuan Ding et al.

Summary: Twenty relapsed B-ALL patients after HSCT were treated with CAR T cell therapy in this study, showing satisfactory initial efficacy and safety. However, the occurrence of aGVHD in patients with a history of haploidentical transplantation receiving allogeneic CAR T cells requires clinical attention.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Review Oncology

Indications for Allogeneic HCT in Adults with Acute Lymphoblastic Leukemia in First Complete Remission

Shukaib Arslan et al.

Summary: The treatment paradigm for ALL in adults, particularly the role of alloHCT, needs to be reevaluated with individualized decision-making. Advances in treatment options require consideration of various factors for complex decision-making.

CURRENT TREATMENT OPTIONS IN ONCOLOGY (2021)

添加到收藏夹

Review Hematology

Therapeutic strategies, including allogeneic stem cell transplantation, to overcome relapsed/refractory adult T-cell acute lymphoblastic leukemia

Dong Won Baek et al.

Summary: For relapsed/refractory adult T-cell acute lymphoblastic leukemia (T-ALL), cytoreductive therapy followed by allogeneic stem cell transplantation (allo-SCT) is considered the most effective treatment approach. Achieving minimal residual disease (MRD) and utilizing posttransplant therapies such as donor leukocyte infusion and hypomethylating agents are crucial for improving clinical outcomes in R/R T-ALL patients.

EXPERT REVIEW OF HEMATOLOGY (2021)

添加到收藏夹

Article Oncology

Repetitively Administered Low-Dose Donor Lymphocyte Infusion for Prevention of Relapse after Allogeneic Stem Cell Transplantation in Patients with High-Risk Acute Leukemia

Panagiotis Tsirigotis et al.

Summary: The study demonstrates that prolonged up to three years of low-dose pro-DLI administered every two months is safe and effective in reducing relapse rate in patients with high-risk acute leukemia. The strategy of low-dose repetitive administration DLI reduces the risk of GVHD and helps in preventing relapse by inducing sustained immunological pressure on residual leukemic cells. Further testing in larger cohorts is warranted to confirm the efficacy of this novel approach in high-risk acute leukemia patients.

CANCERS (2021)

添加到收藏夹

Article Oncology

Maintenance Treatment With Low-Dose Decitabine After Allogeneic Hematopoietic Cell Transplantation in Patients With Adult Acute Lymphoblastic Leukemia

Jia Liu et al.

Summary: The study suggests that maintenance treatment with low-dose decitabine may help reduce relapse in adult ALL patients after allo-HSCT, especially in T-ALL patients. The occurrence of GVHD is relatively low during treatment, indicating good safety profile.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Article Hematology

Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience

Guillaume Richard-Carpentier et al.

Summary: The study confirmed the poor prognosis of ALL with any KMT2A rearrangement and the role of HSCT in improving survival rates for these patients. While the complete remission rate was high, the 5-year overall survival rate remained low, with HSCT showing potential to improve outcomes for this patient population.

BLOOD ADVANCES (2021)

添加到收藏夹

Letter Oncology

Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell/CD19/CD22-negative acute lymphoblastic leukemia

Yishai Ofran et al.

LEUKEMIA (2020)

添加到收藏夹

Article Biophysics

Dose escalation prophylactic donor lymphocyte infusion after T-cell depleted matched related donor allogeneic hematopoietic cell transplantation is feasible and results in higher donor chimerism, faster immune re-constitution, and prolonged progression-free survival

Shawn Kothari et al.

BONE MARROW TRANSPLANTATION (2020)

添加到收藏夹

Article Oncology

Optimizing the use of the hyperCVAD regimen: Clinical vignettes and practical management

Caitlin R. Rausch et al.

CANCER (2020)

添加到收藏夹

Review Hematology

Management of toxicities associated with novel immunotherapy agents in acute lymphoblastic leukemia

Tania Jain et al.

THERAPEUTIC ADVANCES IN HEMATOLOGY (2020)

添加到收藏夹

Review Hematology

Evaluation and management of measurable residual disease in acute lymphoblastic leukemia

Iman Abou Dalle et al.

THERAPEUTIC ADVANCES IN HEMATOLOGY (2020)

添加到收藏夹

Article Hematology

Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Ali Bazarbachi et al.

HAEMATOLOGICA (2020)

添加到收藏夹

Article Hematology

Impact of TKIs post-allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive ALL

Neeraj Saini et al.

BLOOD (2020)

添加到收藏夹

Letter Hematology

CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia

Jyoti Naik et al.

HAEMATOLOGICA (2019)

添加到收藏夹

Review Oncology

Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Iman Abou Dalle et al.

CURRENT TREATMENT OPTIONS IN ONCOLOGY (2019)

添加到收藏夹

Article Hematology

Blinatumomab for Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation

Anthony S. Stein et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)

添加到收藏夹

Article

Relapse Prevention with Tyrosine Kinase Inhibitors after Allogeneic Transplantation for Ph+ ALL, A Systematic Review

Zabih Warraich et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)

添加到收藏夹

Meeting Abstract Hematology

Inotuzumab Ozogamicin Post-Transplant for Acute Lymphocytic Leukemia

Leland Metheny et al.

BLOOD (2019)

添加到收藏夹

Article Biophysics

A retrospective comparison of allogenic and autologous chimeric antigen receptor T cell therapy targeting CD19 in patients with relapsed/refractory acute lymphoblastic leukemia

Yongxian Hu et al.

BONE MARROW TRANSPLANTATION (2019)

添加到收藏夹

Article Biophysics

Prognosis of relapse after hematopoietic cell transplant (HCT) for treatment of leukemia or myelodysplastic syndrome (MDS) in children

Ann Dahlberg et al.

BONE MARROW TRANSPLANTATION (2019)

添加到收藏夹

Article Hematology

Reducing minimal residual disease with blinatumomab prior to HCT for pediatric patients with acute lymphoblastic leukemia

Amy K. Keating et al.

BLOOD ADVANCES (2019)

添加到收藏夹

Article Hematology

Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia

Karen L. Bride et al.

BLOOD (2018)

添加到收藏夹

Article Hematology

Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia

Nicola Goekbuget et al.

BLOOD (2018)

添加到收藏夹

Article

ASBMT Statement on Routine Prophylaxis for Central Nervous System Recurrence of Acute Lymphoblastic Leukemia following Allogeneic Hematopoietic Cell Transplantation

Craig S. Sauter et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)

添加到收藏夹

Meeting Abstract Hematology

Concomitant Use of Blinatumomab and Donor Lymphocyte Infusion for Post-Transplant Relapsed CD19 Positive Acute Lymphoblastic Leukemia: Systematic Review

Ceren Durer et al.

BLOOD (2018)

添加到收藏夹

Article Hematology

Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults

Nitin Jain et al.

BLOOD (2017)

添加到收藏夹

Article Oncology

Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease

Ghayas C. Issa et al.

CANCER (2017)

添加到收藏夹

Letter Hematology

Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia

Nicola Goekbuget et al.

HAEMATOLOGICA (2017)

添加到收藏夹

Article Medicine, General & Internal

Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

Hagop Kantarjian et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Letter Hematology

Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia

Nicola Goekbuget et al.

HAEMATOLOGICA (2017)

添加到收藏夹

Article Hematology

Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft-versus-Host Disease-Guided Multiple DLIs Could Improve Outcomes after Allogeneic Hematopoietic Stern Cell Transplantation in Patients with Refractory/Relapsed Acute Leukemia

Chen-Hua Yan et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)

添加到收藏夹

Meeting Abstract Hematology

Post-Allogeneic Stem Cell Transplantation Maintenance Dasatinib in Philadelphia Chromosome Positive Acute Leukemia

Keri Renee Maher et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)

添加到收藏夹

Article Hematology

Murine allogeneic CD19 CAR T cells harbor potent antileukemic activity but have the potential to mediate lethal GVHD

Elad Jacoby et al.

BLOOD (2016)

添加到收藏夹

Article Hematology

Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia

Farhad Ravandi et al.

BRITISH JOURNAL OF HAEMATOLOGY (2016)

添加到收藏夹

Review Oncology

Use of Tyrosine Kinase Inhibitors to Prevent Relapse After Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Position Statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Sebastian Gebel et al.

CANCER (2016)

添加到收藏夹

Article Medicine, Research & Experimental

CD19 CAR-T cells of defined CD4+: CD8+ composition in adult B cell ALL patients

Cameron J. Turtle et al.

JOURNAL OF CLINICAL INVESTIGATION (2016)

添加到收藏夹

Article Medicine, General & Internal

Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia

Hagop M. Kantarjian et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

添加到收藏夹

Article Oncology

Phase 1/2 Study of Nilotinib Prophylaxis After Allogeneic Stem Cell Transplantation in Patients With Advanced Chronic Myeloid Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Avichai Shimoni et al.

CANCER (2015)

添加到收藏夹

Article Hematology

Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia

Eolia Brissot et al.

HAEMATOLOGICA (2015)

添加到收藏夹

Article Hematology

ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia

Sofie Peirs et al.

BLOOD (2014)

添加到收藏夹

Article Hematology

Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia

Kheira Beldjord et al.

BLOOD (2014)

添加到收藏夹

Review Oncology

The Biology of Relapsed Acute Lymphoblastic Leukemia: Opportunities for Therapeutic Interventions

Teena Bhatla et al.

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2014)

添加到收藏夹

Editorial Material Oncology

Understanding anti-leukemia responses to donor lymphocyte infusion

Pavan Bachireddy et al.

ONCOIMMUNOLOGY (2014)

添加到收藏夹

Article Oncology

Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia

H. Pfeifer et al.

LEUKEMIA (2013)

添加到收藏夹

Article Hematology

Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation

Chen-Hua Yan et al.

BLOOD (2012)

添加到收藏夹

Article Hematology

Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategies

Laura E. Hogan et al.

BLOOD (2011)

添加到收藏夹

Article Oncology

Intensified chemotherapy inspired by a pediatric regimen combined with allogeneic transplantation in adult patients with acute lymphoblastic leukemia up to the age of 40

A. W. Rijneveld et al.

LEUKEMIA (2011)

添加到收藏夹

Article Education, Scientific Disciplines

Minimal Residual Disease in Acute Lymphoblastic Leukemia

Dario Campana

HEMATOLOGY-AMERICAN SOCIETY HEMATOLOGY EDUCATION PROGRAM (2010)

添加到收藏夹

Letter Hematology

Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia

Alida Dominietto et al.

BLOOD (2007)

添加到收藏夹

Article Hematology

Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial

Anthony V. Moorman et al.

BLOOD (2007)

添加到收藏夹

Article Hematology

Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children's Oncology Group study

Deepa Bhojwani et al.

BLOOD (2006)

添加到收藏夹

Article Hematology

Responses to donor lymphocyte infusion for acute lymphoblastic leukemia may be determined by both qualitative and quantitative limitations of antileukemic T-cell responses as observed in an animal model for human leukemia

BA Nijmeijer et al.

EXPERIMENTAL HEMATOLOGY (2005)

添加到收藏夹

Article Biophysics

Donor leukocyte infusions in acute lymphocytic leukemia

RH Collins et al.

BONE MARROW TRANSPLANTATION (2000)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.